Wedekind, Dirk

[["dc.bibliographiccitation.journal","European Psychiatry"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Croissant, B."],["dc.contributor.author","Boehler, J."],["dc.contributor.author","Lorenz, Jan L."],["dc.contributor.author","Diehl, A."],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Mann, K."],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T08:47:37Z"],["dc.date.available","2018-11-07T08:47:37Z"],["dc.date.issued","2010"],["dc.identifier.isi","000208225801265"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20999"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier France-editions Scientifiques Medicales Elsevier"],["dc.publisher.place","Paris"],["dc.relation.issn","0924-9338"],["dc.title","RCT: QUETIAPINE VS. PLACEBO IN ALCOHOL RELAPSE PREVENTION. RATIONAL, METHODS AND PRELIMINARY RESULTS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","133"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","138"],["dc.bibliographiccitation.volume","261"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Neumann, Karolin"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Engel, Kirsten Rita"],["dc.contributor.author","Jamrozinski, Katja"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T08:58:43Z"],["dc.date.available","2018-11-07T08:58:43Z"],["dc.date.issued","2011"],["dc.description.abstract","Elevations of serum homocysteine levels are a consistent finding in alcohol addiction. Serum S100B levels are altered in different neuropsychiatric disorders but not well investigated in alcohol withdrawal syndromes. Because of the close connection of S100B to ACTH and glutamate secretion that both are involved in neurodegeneration and symptoms of alcoholism the relationship of S100B and homocysteine to acute withdrawal variables has been examined. A total of 22 male and 9 female inpatients (mean age 46.9 +/- A 9.7 years) with an ICD-10 diagnosis of alcohol addiction without relevant affective comorbidity were examined on admission and after 24, 48, and 120 h during withdrawal. S100B and homocysteine levels in serum were collected, and severity of withdrawal symptoms (AWS-scale), applied withdrawal medication, initial serum ethanol levels and duration of addiction were recorded. Serum S100B and homocysteine levels declined significantly (P < .05) over time. Both levels declined with withdrawal syndrome severity. Females showed a trend to a more intense decline in serum S100B levels compared to males at day 5 (P = .06). Homocysteine levels displayed a negative relationship to applied amount of clomethiazole (P < .05) and correlated with age of onset of addiction. No withdrawal seizures were recorded during the trial. As it is known for homocysteine, S100B revealed to decline rapidly over withdrawal treatment in alcoholism. This effect is more pronounced in female patients. S100B could be of relevance in the neurobiology of alcohol withdrawal syndromes. It may be indirectly related to the level of stress level or glutamatergic activity during alcohol withdrawal."],["dc.identifier.doi","10.1007/s00406-010-0121-2"],["dc.identifier.isi","000287859300007"],["dc.identifier.pmid","20593192"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6616"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23711"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","0940-1334"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","S100B and homocysteine in the acute alcohol withdrawal syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1163"],["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","Journal of Psychiatric Research"],["dc.bibliographiccitation.lastpage","1169"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Herchenhein, Thomas"],["dc.contributor.author","Kirchhainer, Julia"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Engel, Kirsten"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T08:36:24Z"],["dc.date.available","2018-11-07T08:36:24Z"],["dc.date.issued","2010"],["dc.description.abstract","Alcohol addiction is associated with alterations of central nervous dopaminergic and serotonergic functions. Acute tryptophan depletion has not yet been applied in detoxified alcohol-addicted patients in order to investigate its impact on psychopathology, psychoneuroendocrinology, and substance craving behaviour. 25 alcohol-addicted males randomly either received a tryptophan-free or tryptophan-containing amino acid drink and 7 days later the respective other drink. Anxiety, depression, and craving were assessed before and 5 h after the drink. Tryptophan, 5-HIAA, dopamine, norepinephrine, epinephrine, and HVA in serum were measured before and after both treatments. Nocturnal urinary cortisol measurements and genotyping for the HTTLPR polymorphism of the SLC6A4 gene were performed. Tryptophan depletion resulted in a significant reduction of total and free serum tryptophan while the tryptophan-rich drink increased serum levels. Both treatments caused a significant increase of serum serotonin levels, however, serum 5-HIAA was decreased after depletion but increased after sham depletion. Dopamine and norepinephrine were elevated after tryptophan depletion and sham. Depletion increased depression scores (MADRS), while the full amino acid drink improved state and trait anxiety ratings (STAI) and substance craving. Urinary cortisol excretion was not affected by both treatments. Patients with the II genotype of the serotonin transporter gene displayed lower baseline tryptophan levels compared to patients with the heterozygous genotype. Results suggest an impaired serotonergic function in alcohol-addicted males. (C) 2010 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.jpsychires.2010.04.002"],["dc.identifier.isi","000285952000007"],["dc.identifier.pmid","20579662"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18303"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0022-3956"],["dc.title","Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.contributor.author","Hart, X. M."],["dc.contributor.author","Heesen, S."],["dc.contributor.author","Schmitz, C. N."],["dc.contributor.author","Dörfler, S."],["dc.contributor.author","Wedekind, D."],["dc.contributor.author","Gründer, G."],["dc.contributor.author","Hiemke, C."],["dc.contributor.author","Havemann-Reinecke, U."],["dc.date.accessioned","2022-11-01T10:17:36Z"],["dc.date.available","2022-11-01T10:17:36Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\n The selective serotonin reuptake inhibitor escitalopram (ESC) is indicated for the treatment of major depressive disorder (MDD) and of generalized anxiety disorder (GAD). Monitoring of blood levels (BLs) is strongly indicated due to ESC’s high interindividual pharmacokinetic variability. The aim of this study was to analyse clinical efficacy and pharmacokinetic influences on ESC BLs, in patients with depressive disorder alone and with comorbid alcohol or benzodiazepine use disorder. Data were collected from patients treated under naturalistic conditions for whom Therapeutic Drug Monitoring (TDM) was requested to guide antidepressant drug therapy and analysed retrospectively. Particular emphasis was given to patients with alcohol or benzodiazepine use disorder. Responders according to the clinical global impression (CGI) scale were compared with nonresponders for their ESC blood level (BL). The patient sample included 344 patients from 16 psychiatric hospitals in Germany. Influencing factors that could explain 22% of ESC BLs were dose, sex and age. Variability was high between individuals, and doses up to 40 mg were common in real-world settings. Patients treated with ESC monotherapy who responded showed a trend towards higher BLs compared to nonresponders with a concentration of 15 ng/mL separating both groups. Pathological changes in liver function (indicated by elevated GGT in combination with an AST/ALT ratio ≥ 1) resulted in higher dose-corrected ESC concentrations. Influencing factors that could explain 22% of ESC blood levels were dose, sex, and age. Our findings confirm the currently recommended lower threshold level and support the need for standard TDM analyses in everyday clinical practice. The ICD 10 diagnosis alcohol dependence alone does not lead to pharmacokinetic changes in the metabolism of ESC, but altered liver function does."],["dc.identifier.doi","10.1007/s00406-022-01491-9"],["dc.identifier.pii","1491"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/116855"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-605"],["dc.relation.eissn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","225"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Psychoactive Drugs"],["dc.bibliographiccitation.lastpage","232"],["dc.bibliographiccitation.volume","49"],["dc.contributor.author","Mergler, Michaela"],["dc.contributor.author","Driessen, Martin"],["dc.contributor.author","Lüdecke, Christel"],["dc.contributor.author","Ohlmeier, Martin"],["dc.contributor.author","Chodzinski, Claudia"],["dc.contributor.author","Weirich, Steffen"],["dc.contributor.author","Schläfke, Detlef"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Renner, Walter"],["dc.contributor.author","Schäfer, Ingo"],["dc.date.accessioned","2020-12-10T18:14:50Z"],["dc.date.available","2020-12-10T18:14:50Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1080/02791072.2017.1296209"],["dc.identifier.eissn","2159-9777"],["dc.identifier.issn","0279-1072"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74633"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Relationships between a Dissociative Subtype of PTSD and Clinical Characteristics in Patients with Substance Use Disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","German Journal of Psychiatry"],["dc.bibliographiccitation.lastpage","7"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Jacobs, Stefan"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Schneider, Udo"],["dc.contributor.author","Cimander, Konrad"],["dc.contributor.author","Engel, Kirsten"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2019-07-10T08:13:27Z"],["dc.date.available","2019-07-10T08:13:27Z"],["dc.date.issued","2009"],["dc.description.abstract","Objective: Previous reports on heroin and cocaine addicts showed drug-related and gender differences in psychiatric comorbidity, which has relevant consequences for treatment. However, studies vary substantially with respect to methods and timeframes. Studies on German patient groups are scarce. Methods: Data on psychiatric and somatic comorbidity, substance addiction history, present intake patterns and sociodemography were obtained from 43 female (n=11) and male (n=32) heroin and cocaine addicts in acute inpatient detoxification treatment or specified long-term treatment. A European Addiction-Severity-Index (EuropASI) based centre questionnaire and the Mini-DIPS were applied. Results: Treatment groups did not differ in psychiatric comorbidity. Female subjects, however, had a significantly higher prevalence of psychiatric comorbid diagnoses (p<.05), mostly anxiety and affective disorders which significantly correlated with low occupational status (p<.05).Patients in long-term treatment abused more other substances and had an earlier onset of regular substance abuse (in particular alcohol and cannabis) (p<.05). Conclusion: Heroin and cocaine addicted females are more likely than males to have affective and anxiety disorders. Long-term treatment attenders appear to be more severely addicted (earlier onset and additional abuse) than acute treatment patients but do not differ in comorbidity. However, no axis-II diagnoses were recorded and the sample-size was small. Results should be regarded as preliminary (German J Psychiatry 2009; 12: 1-7)."],["dc.identifier.fs","541930"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5950"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/61249"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1455-1033"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Psychiatric Comorbidity and Gender Effects in Heroin and Cocaine-Addicted Patients in Specified Long-Term Treatment and Acute Inpatient Detoxification Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Brueckner, A."],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Genee, C."],["dc.contributor.author","Hiemke, Christoph"],["dc.date.accessioned","2018-11-07T10:59:20Z"],["dc.date.available","2018-11-07T10:59:20Z"],["dc.date.issued","2007"],["dc.format.extent","209"],["dc.identifier.isi","000249873600026"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50676"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","25th Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Factors affecting the pharmacokinetics of escitalopram - Data from a naturalistic study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","57"],["dc.bibliographiccitation.journal","Journal of Substance Abuse Treatment"],["dc.bibliographiccitation.lastpage","63"],["dc.bibliographiccitation.volume","93"],["dc.contributor.author","Mergler, Michaela"],["dc.contributor.author","Driessen, Martin"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Lüdecke, Christel"],["dc.contributor.author","Ohlmeier, Martin"],["dc.contributor.author","Chodzinski, Claudia"],["dc.contributor.author","Teunißen, Sibylle"],["dc.contributor.author","Weirich, Steffen"],["dc.contributor.author","Kemper, Ulrich"],["dc.contributor.author","Renner, Walter"],["dc.contributor.author","Schäfer, Ingo"],["dc.date.accessioned","2020-12-10T14:25:25Z"],["dc.date.available","2020-12-10T14:25:25Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.jsat.2018.07.010"],["dc.identifier.issn","0740-5472"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72550"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Differential relationships of PTSD and childhood trauma with the course of substance use disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Journal of Substance Use"],["dc.bibliographiccitation.lastpage","5"],["dc.contributor.author","Gidzgier, Piotr"],["dc.contributor.author","Driessen, Martin"],["dc.contributor.author","Gawęda, Łukasz"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Lüdecke, Christel"],["dc.contributor.author","Ohlmeier, Martin"],["dc.contributor.author","Weirich, Steffen"],["dc.contributor.author","Kemper, Ulrich"],["dc.contributor.author","Schäfer, Ingo"],["dc.date.accessioned","2021-08-12T07:45:10Z"],["dc.date.available","2021-08-12T07:45:10Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1080/14659891.2021.1941357"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88387"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.relation.eissn","1475-9942"],["dc.relation.issn","1465-9891"],["dc.title","Validation of the extended version of the Dissociative Experiences Scale (DES) in patients diagnosed with substance use disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","509"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","NERVENHEILKUNDE"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T08:35:12Z"],["dc.date.available","2018-11-07T08:35:12Z"],["dc.date.issued","2009"],["dc.description.abstract","Comorbid psychiatric disorders are a common finding in substance addicted subjects. They have an enormous impact on treatment costs, course and restriction in quality of life. Data from our research group are presented which, according to recent scientific literature, demonstrate a high prevalence of psychiatric morbidity in alcohol-, opioid-, and nicotine-addicted individuals, before all of anxiety- and affective disorders. Seen from a different point of view a high prevalence of harmful substance use can be observed in patients with anxiety disorders or with borderline personality disorder. Substances abused are mostly alcohol and benzodiazepines. These findings may be related to possible dysfunctions of distinct central nervous transmitter systems."],["dc.identifier.isi","000270061100002"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18005"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0722-1541"],["dc.title","Substance addiction, comorbidity, and central nervous transmitter systems"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]